Last reviewed · How we verify

NCT07096817

Effects of a Highly Intensive Balance Therapy Camp in Children With Developmental Coordination Disorder

Completed NA Last updated 31 July 2025
What this trial tests

NA trial testing Highly intensive individualized balance therapy in Developmental Coordination Disorder in 35 participants. Completed in 30 November 2024.

Timeline
2 November 2022
Primary endpoint
30 November 2024
30 November 2024

Quick facts

Lead sponsorHasselt University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment35
Start date2 November 2022
Primary completion30 November 2024
Estimated completion30 November 2024
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Hasselt University

Who can join

Adults 6 to 12, any sex, with Developmental Coordination Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this clinical trial is to investigate the short (immediately after intervention) and medium term (three month) effects of a highly intensive, comprehensive postural control 6-day therapy camp in school-aged children (6 to 12 years) with developmental coordination disorder at different levels of the The International Classification of Functioning, Disability and Health (ICF) framework.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Developmental Coordination Disorder

Currently open trials in the same condition.

Other Hasselt University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07096817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing